PDS Biotechnology (NASDAQ:PDSB) Price Target Raised to $15.00

PDS Biotechnology (NASDAQ:PDSB) had its price target raised by HC Wainwright from $13.00 to $15.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, PDS Biotechnology currently has a consensus rating of “Hold” and an average price target of $11.00.

PDS Biotechnology Trading Down 0.5%

Shares of PDSB opened at $0.84 on Thursday. PDS Biotechnology has a 1-year low of $0.84 and a 1-year high of $2.46. The company has a market capitalization of $39.53 million, a P/E ratio of -0.91 and a beta of 1.06. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.92 and a quick ratio of 2.92. The firm’s 50 day simple moving average is $1.00 and its 200 day simple moving average is $1.22.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. Sell-side analysts forecast that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. Tempus Wealth Planning LLC grew its stake in shares of PDS Biotechnology by 154.3% during the second quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company’s stock valued at $64,000 after buying an additional 29,000 shares during the last quarter. Watts Gwilliam & Co. LLC purchased a new stake in PDS Biotechnology during the 2nd quarter valued at about $73,000. Marshall Wace LLP bought a new position in PDS Biotechnology during the 2nd quarter worth approximately $91,000. Jane Street Group LLC bought a new position in PDS Biotechnology during the 2nd quarter worth approximately $92,000. Finally, Iron Gate Global Advisors LLC purchased a new position in PDS Biotechnology in the 1st quarter worth approximately $89,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.